The one thing Bryan Johnson hates doing on shrooms is talking: Best moments from his 6 hour Magic Mushrooms Trip

Ben King

Bryan Johnson’s six-hour psychedelic marathon captivated over a million viewers last night, offering an unfiltered window into what happens when someone takes a five-gram dose of magic mushrooms with cameras rolling.

But perhaps the most revealing moment came when he tried to explain why conversation felt impossible at the height of his journey.

“You don’t want to speak because speech detracts from the beauty,” Johnson said during the stream, his words arriving slowly and deliberately. “It’s like this lower dimensional expression and sensory experience is so much more rich. And speech feels like it takes away from it. Like that you go from something like ten dimensional living dimensions of experience that back down to two.”

The tech entrepreneur didn’t rely on post-production magic or careful editing. Viewers watched him consume the entire dose on camera, complete with lemon juice to ensure nothing went to waste.

This marked his second session in a planned trilogy, and he was clearly determined to address the criticism from his first attempt—where viewers felt misled about the actual dosage.

What set this stream apart from typical internet stunts was the caliber of guests Johnson assembled.

Naval Ravikant, Hamilton Morris, and Marc Benioff joined the broadcast to discuss the therapeutic potential of psychedelics, transforming what could have been pure entertainment into something resembling a public symposium on consciousness and mental health treatment.

During the stream, Naval Ravikant didn’t mince words about his frustration with the current state of medical progress. “The FDA slows everything down, and we’re all going to die by the time they get there,” he stated bluntly.

It’s a sentiment that resonates with anyone who has followed medical news. Week after week, headlines trumpet breakthrough cancer treatments and revolutionary therapies, only for these promising discoveries to vanish into the regulatory labyrinth.

“You read about a cancer cure every week, and then it never comes to fruition. Nothing gets tested, nothing gets deployed, everything’s too dangerous, bioethicists everywhere, regulations everywhere, right to try is basically not real,” Ravikant explained.

This is where Bryan Johnson’s controversial self-experimentation enters the picture. Rather than waiting for institutional approval, Johnson has taken matters into his own hands, becoming what Ravikant called “a one-man FDA.”

The approach is simple but radical: “He’s like, screw it, I’ll just do everything to myself, and I’ll legitimize it, I’ll popularize it, I’ll experiment with it, and I’m going to blaze the trail.”

For Ravikant, Johnson represents a necessary disruption to an overly cautious system. “So, you know, God bless him. I hope he survives for a long time, and then give us the cheat codes. That’s really what we want.”

The conversation also turned to a specific area where regulatory caution may be causing unnecessary suffering: the medical use of psychedelics. Hamilton Morris highlighted the case of cluster headaches, a condition so excruciating that it sometimes drives sufferers to desperate measures. “I’ve heard of people getting prescribed c**aine, things that are typically only prescribed under the most extreme circumstances are prescribed for cluster headaches because it’s so debilitating and so severe.”

The cruel irony is that effective treatments may already exist. “And it turns out that cluster headaches are very responsive to psychedelics, and actually to a variety of different psychedelics,” Morris explained. Yet accessing these treatments remains extraordinarily difficult for patients who need them most.

The experimental element reached new heights when Johnson strapped on a portable brain scanner from Kernel, the neurotechnology company he’s championed for years.

Traditional brain scanning equipment often requires clinical settings and can be uncomfortable for subjects. The Kernel approach aims to democratize brain imaging by making it as simple as possible.

“It’s not the most pleasant,” his co-host noted about conventional brain scanning methods. “Whereas with Kernel, you can kind of throw the headset on and it’s very easy. It’s like wearing a bike helmet.”

Musical curation came courtesy of Grimes, whose selections visibly altered the trajectory of Johnson’s experience. Anyone who has navigated psychedelic territory knows how profoundly sound can shape the journey, and her involvement added an element of intentional ceremony to the proceedings.

The intensity hit Johnson harder than anticipated. His face betrayed the overwhelming nature of what he was experiencing—this wasn’t the gentle, nostalgic first journey he’d described previously.

Perhaps the most humanizing aspect arrived through his son’s appearances, checking in before, during, and after the peak. These weren’t staged interactions but genuine moments of family connection around something inherently vulnerable and unpredictable.

Johnson’s son reflected on the unique challenges of explaining his father’s activities to curious friends. When asked about his dad’s work, he admitted struggling to find the right words before landing on a decidedly modern answer: “He like occasionally like trips balls on X in front of hundreds of thousands of people.”

What stands out most in the exchange, however, isn’t the spectacle itself but the supportive dynamic between father and son. Johnson’s son has earned praise from observers for his steadfast encouragement of his father’s unconventional pursuits.

“A lot of other people in this circumstance might be like this is a bad idea don’t do it,” he noted, describing his own response as fundamentally different: “He’s always like I got you dad like go go play have fun.”

At some point during the peak, uncontrollable laughter took over. The backlash arrived predictably. Critics attacked his language choices, questioned the ethics of broadcasting such an experience, and dismissed the entire production as self-promotion.

Yet the numbers told a different story: millions tuned in, and much of the resulting conversation centered on legitimate therapeutic applications rather than sensationalism.

Ben King